Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary disease.
Ismigen, a polyvalent mechanical bacterial lysate, is also used to prevent acute, sub-acute, recurrent or chronic infections of the upper and lower airways and the bronchopulmonary tree.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The drug is prepared from a large array of inactivated pathogenic bacteria via mechanical lysis.
Switzerland-based Lallemand Pharma’s key products are comprised of immunostimulant drugs Ismigen, Immubron and Respibron, which target infections of the respiratory tract.
